What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2026-04-16 compared with 2026-02-19 · 160 added, 153 removed, 599 unchanged (34% of the section changed)

2 unchanged sentences

CONSOLIDATED BALANCE SHEETS

November 30, 2025

February 28, 2026

CURRENT ASSETS

18 unchanged sentences

STOCKHOLDERS’ DEFICIENCY

10,000,000 shares of preferred stock, without par value, of which 2,500,000 shares have been designated Series A Convertible Preferred Stock ( 2,500,000 shares outstanding at November 30, 2025, and May 31, 2025) and 2,000 shares have been designated Series B Preferred Stock ( 2,000 shares outstanding at November 30, 2025, and May 31, 2025)

10,000,000 shares of preferred stock, without par value, of which 2,500,000 shares have been designated Series A Convertible Preferred Stock ( 2,500,000 shares outstanding at February 28, 2026, and May 31, 2025) and 2,000 shares have been designated Series B Preferred Stock ( 2,000 shares outstanding at February 28, 2026, and May 31, 2025)

Common Stock, without par value:

20,000,000,000 shares authorized, of which 11,626,749,347 shares were issued and outstanding at November 30, 2025, and May 31, 2025

20,000,000,000 shares authorized, of which 11,626,749,347 shares were issued and outstanding at February 28, 2026, and May 31, 2025

Additional paid-in capital

10 unchanged sentences

CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended November 30,

Six Months Ended November 30,

Three Months Ended February 28,

Nine Months Ended February 28,

Cost of revenues

12 unchanged sentences

Change in fair value of derivative liabilities

Other Income/Loss

Total other income (expense)

2 unchanged sentences

$ ( 303,546 )

Average common stock outstanding

$ ( 337,076 )

Weighted average common stock outstanding

11,626,749,347

1 unchanged sentence

11,626,749,347

Average earnings (loss) per share

10,573,938,169

Weighted average earnings (loss) per share

$ ( 0.000009 )

1 unchanged sentence

$ ( 0.000026 )

$ ( 0.0000032 )

See accompanying notes to consolidated financial statements.

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS,

CANNABIS BIOSCIENCE INTERNATIONAL

HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Six Months Ended November 30,

Nine Months Ended February 28,

CASH FLOW FROM OPERATING ACTIVITIES:

Net income (loss)

$ ( 303,546 )

$ ( 337,076 )

Adjustment to reconcile net cash used in operations:

Adjustment to reconcile net income (loss) to cash used in operations:

Issuance of common stock for services

Amortization of right-of-use asset and liability

Interest Expense

Change in value of derivative liabilities

3 unchanged sentences

Related Party Payable

Related Party Receivables

Lease liability (net)

1 unchanged sentence

CASH FLOW FROM FINANCING ACTIVITIES:

Issuance of Common Stock

Proceeds from (repayments of) short-term loans

Proceeds from (payment of) notes payable

Payment of notes payable

Repayment of SBA loans

11 unchanged sentences

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIENCY

FOR THE SIX MONTHS ENDED NOVEMBER 30, 2025

A Convertible Preferred Stock

Preferred Stock

FOR THE NINE MONTHS ENDED FEBRUARY 28, 2026

Series A Convertible Preferred Stock

Series B Preferred Stock

Additional Paid-In

13 unchanged sentences

$ ( 1,363,195 )

Net loss for the quarter

Balance – February 28, 2026

11,626,749,347

$ ( 6,186,448 )

$ ( 1,467,130 )

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIENCY

FOR THE SIX MONTHS ENDED NOVEMBER 30, 2024

A Convertible Preferred Stock

Preferred Stock

FOR THE NINE MONTHS ENDED FEBRUARY 28, 2025

Series A Convertible Preferred Stock

Series B Preferred Stock

Additional Paid-In

5 unchanged sentences

Issuance of shares of Series B Preferred

Net income for the quarter

Net loss for the quarter

Balance - August 31, 2024

2 unchanged sentences

$ ( 1,055,318 )

Net income for the quarter

Net loss for the quarter

Balance – November 30, 2024

2 unchanged sentences

$ ( 1,134,846 )

Net loss for the quarter

Balance – February 28, 2025

10,981,749,347

$ ( 5,671,157 )

$ ( 1,225,589 )

See accompanying notes to consolidated financial statements.

1 unchanged sentence

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

November 30, 2025

February 28, 2026

Note 1 – Organization and Operations

26 unchanged sentences

unaudited consolidated financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present

the financial position of the Company at November 30, 2025, and the results of operations and cash flows for the periods presented.

results of operations for the three months ended November 30, 2025, are not necessarily indicative of the operating results for the full

the financial position of the Company at February 28, 2026, and the results of operations and cash flows for the periods presented.

results of operations for the nine months ended February 28, 2026, are not necessarily indicative of the operating results for the full

fiscal year or any future period.

These unaudited consolidated financial statements should be read in conjunction with the Company’s

audited consolidated financial statements and related notes thereto for the year ended May 31, 2025, filed with the SEC on September 22,

2025, as part of the Company’s Annual Report on Form 10-K.

audited consolidated financial statements and related notes thereto for the year ended May 31, 2025, filed with the U.S.

Securities and

Exchange Commission on September 22, 2025, as part of the Company’s Annual Report on Form 10-K.

Use of Estimates

24 unchanged sentences

The Company had no investment

securities that were deemed cash equivalents at November 30, 2025, and May 31, 2025.

securities that were deemed cash equivalents at February 28, 2026, and May 31, 2025.

Accounts Receivable

6 unchanged sentences

Based upon experience and the judgment of management, there

was no allowance for doubtful accounts at November 30, 2025, and May 31, 2025.

was no allowance for doubtful accounts at February 28, 2026, and May 31, 2025.

Revenue Recognition

26 unchanged sentences

less or if the amount is immaterial.

A performance obligation is a contractual

promise to transfer a distinct product or service to a customer and is the unit of account in the new revenue standard.

transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance

obligation is satisfied.

Each contract has a single performance obligation as the promise to transfer the individual goods or

services is not separately identifiable from other promises in the contract and, therefore, not distinct.

Revenue from contracts

that satisfy the criteria for overtime recognition is recognized as the work progresses.

The majority of the Company’s revenue

is derived from services provided to customers and is typically executed over a period that is typically between 1 and 12 months,

based on evaluation of when these services are rendered.

Contracts will continue to be recognized over time because of the

continuous transfer of control to the customer as services are rendered to customers.

Payments made by customers in advance of

services being rendered are recorded as deferred revenue.

A performance obligation is a contractual promise

to transfer a distinct product or service to a customer and is the unit of account in the new revenue standard.

The contract transaction

price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied.

Each contract has a single performance obligation as the promise to transfer the individual goods or services is not separately identifiable

from other promises in the contract and, therefore, not distinct.

Revenue from contracts that satisfy the criteria for overtime recognition

is recognized as the work progresses.

The majority of the Company’s revenue is derived from services provided to customers and is

typically executed y over a period that is typically between 1 and 12 months, based on evaluation of when these services are rendered.

Contracts will continue to be recognized over time because of the continuous transfer of control to the customer as services are rendered

to customers.

Payments made by customers in advance of services being rendered are recorded as deferred revenue.

Our significant payment terms for customer contracts

14 unchanged sentences

Contracts for educational services require nonrefundable

payments in advance and are recorded as revenue when received.

payment in advance and are recorded as revenue when received.

There is no significant financing component to any

Share-Based Compensation

On July 20, 2022, the Company adopted its 2022

Equity Incentive Plan, which provides for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted

stock, unrestricted stock, restricted stock units and performance awards to directors, officers, employees and consultants, as determined

by the Board, as plan administrator.

The Company will recognize as share-based compensation expense all share-based payments to employees

over the requisite service period (generally the vesting period) in its consolidated statements of operations based on the fair values

of the awards that are issued.

Contract Modifications

21 unchanged sentences

of one year or less.

At November 30, 2025, and May 31, 2025, the Company had no remaining performance obligations.

At February 28, 2026, and May 31, 2025, the Company had no remaining performance obligations.

Share-Based Payments

78 unchanged sentences

by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during

At November 30, 2025, and May 31, 2025, the Company had no dilutive securities.

At February 28, 2026, and May 31, 2025, the Company had no dilutive securities.

Recently Issued Accounting Standards

43 unchanged sentences

in annual periods beginning after December 15, 2024, with early adoption permitted.

The Company is currently evaluating the amendments, which are not expected to have an impact on its financial condition or results of operations.

The Company is currently evaluating the provisions

of the amendments, which are not expected to have an impact on its financial condition or results of operations.

The Company expects to

23 unchanged sentences

Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606):

Clarifications to Share-Based Consideration Payable to

a Customer (“ASU 2025-04”), which clarifies the guidance on the accounting for share-based payment awards that are

granted by an entity as consideration payable to its customer, with the intent to reduce diversity in practice and improve existing guidance

by revising the definition of a “performance condition” and eliminating a forfeiture policy election for service conditions

associated with share-based consideration payable to a customer.

ASU 2025-04 also clarifies the guidance in Topic 606 on the variable

consideration constraint does not apply to share-based consideration payable to a customer “regardless of whether an award’s

grant date has occurred.” ASU 2025-04 is effective for our reporting period beginning January 1, 2027, with early adoption permitted.

We are currently assessing the impact that the adoption of ASU 2025-04 will have on the disclosures in our annual consolidated financial

Clarifications to Share-Based Consideration Payable

to a Customer (“ASU 2025-04”), which clarifies the guidance on the accounting for share-based payment awards

that are granted by an entity as consideration payable to its customer, with the intent to reduce diversity in practice and improve

existing guidance by revising the definition of a “performance condition” and eliminating a forfeiture policy election

for service conditions associated with share-based consideration payable to a customer.

ASU 2025-04 also clarifies the guidance in

Topic 606 on the variable consideration constraint does not apply to share-based consideration payable to a customer

“regardless of whether an award’s grant date has occurred.” ASU 2025-04 is effective for our reporting period

beginning January 1, 2027, with early adoption permitted.

We are currently assessing the impact that the adoption of ASU 2025-04

will have on the disclosures in our annual consolidated financial statements.

The Company does not believe there are any other recently

10 unchanged sentences

operating expenses since its inception.

During the six months ended November 30, 2025, the Company had net loss from operations of $ 199,612 ,

During the nine months ended February 28, 2026, the Company had net loss from operations of $ 263,920 ,

net cash used in operations of $ 123,802 , a working capital deficit of $ 1,217,630 and an accumulated deficit of $ 6,186,448 .

The ability of the Company to continue as a going

concern depends on the successful execution of its operating plan, which includes expanding its operations and raising debt or

concern depends on the successful execution of its operating plan, which includes expanding its operations and raising either debt or

equity financing.

9 unchanged sentences

The loan bears interest at the rate of 3.75 % per annum and is payable in monthly installments of $ 698 over a 30 -year period,

with deferral of payments for the first 12 months.

In June 2020, the Company received proceeds of $ 106,200

5 unchanged sentences

Schedule of EIDL loans

November 30, 2025

February 28, 2026

SBA (EIDL) – current

11 unchanged sentences

In May 2022, the Company entered into a financing agreement with an unrelated party for a loan of $ 50,000 , bearing interest at the rate of 20.9 % per annum, to be repaid at the rate of $1,218 per week for one year.

At November 30, 2025, the outstanding balance, including interest, was $ 55,422 This loan is in default.

At February 28, 2026, the outstanding balance, including interest, was $ 55,422 This loan is in default.

In January 2023, the Company entered into a financing agreement with an unrelated party for a loan of $ 20,000 , bearing interest at the rate of 33.5 % per annum, to be repaid at the rate of $1,874 per month.

The outstanding balance at November 30, 2025, was $ 2,921 .

The outstanding balance at February 28, 2026, was $ 2,921 .

Payments under this agreement are in arrears and the Company is negotiating with the unrelated party to reschedule them.

In April 2023, the Company entered into a financing agreement with an unrelated party for a loan of $ 37,475 , bearing interest at the rate of 19 % per annum, to be repaid at the rate of $1,718 per month.

The outstanding balance at November 30, 2025, was $ 36,507 .

The outstanding balance at February 28, 2026, was $ 36,507 .

Payments under this agreement are in arrears and the Company is negotiating with the unrelated party to reschedule them.

On August 8, 2022, the Company entered into a financing agreement with an unrelated party for a loan of $ 45,000 , bearing interest at the rate of 26.4 % per annum, to be repaid at the rate of $6,114 per week for 20 weeks.

As refinanced, the loan was increased to $ 76,000 at the same rate of interest and was to be repaid at the rate of $6,114 per week for 17 weeks.

On May 13, 2024, the Company agreed to settle the $ 38,638 owing under this agreement in consideration of a payment of $ 15,000 , which the Company made on June 12, 2024.

Under ASC 470-50-40, the fair value of extinguished debt, less the fair value of the payment, is treated as gain.

Accordingly, $ 23,638 has been recorded in the Company’s consolidated statement of operations as other income (expense) – Forgiveness of debt.

On October 8, 2019, the Company borrowed $ 12,500 from

an unrelated party bearing interest at the rate of 14 %

per annum (the “Headway Loan”).

This loan was repayable at the weekly rate of $589 for 24 weeks.

On October 13,

2022, an additional loan of $ 6,304 was

obtained with a weekly payment of $297 for 24 weeks.

On October 8, 2019, the Company borrowed $ 12,500 from an unrelated party bearing interest at the rate of 14 % per annum (the “Headway Loan”).

This loan is payable at the weekly rate of $589 for 24 weeks.

On October 13, 2022, an additional loan of $ 6,304 was obtained with a weekly payment of $297 for 24 weeks.

The loan was guaranteed by a related party.

At November 30, 2025, the

outstanding balance of this loan, including interest, was $ 16,871

This loan is in default.

At February 28, 2026, the outstanding balance of this loan, including interest, was $ 16,871 This loan is in default.

Convertible Notes

8 unchanged sentences

The note was repaid on January 12, 2025, at which time, it was not in default.

The note provided that upon an event of default, the holder could convert the amount then unpaid into Common Stock at a conversion price of 65% of the lowest trading price therefor during the 10 trading days prior to the date of conversion.

The note provided that upon an event of default, the holder could convert the amount then unpaid into Common Stock at a conversion price of 65% of the lowest trading price therefore during the 10 trading days prior to the date of conversion.

On November 7, 2024, the Company made a promissory note in the principal amount of $ 67,200 in favor of an unrelated party.

5 unchanged sentences

The balance as of November 30, 2025, was $ 101 .

The balance as of February 28, 2026, was $ 101 .

Related Party Debt

15 unchanged sentences

Schedule of amount related to leases

November 30, 2025

February 28, 2026

Right-of-use asset

4 unchanged sentences

Operating lease liabilities

The Company reimburses a related party for an

operating lease for office space under a month-to-month arrangement, payable at the discretion of management.

The Company’s total operating lease expenses

were $ 22,398 and $ 36,687 during the six months ended November 30, 2025, and November 30, 2024, respectively.

The Company reimburses a related party for an office

space operating lease under a month-to-month arrangement, payable at the discretion of management.

The Company’s total lease expenses

were $ 33,867 and $ 49,957 during the nine months ended February 28, 2026, and February 28, 2025, respectively.

See Note 10 for additional lease information.

11 unchanged sentences

Three Months Ended

Six Months Ended

Nine Months Ended

Clinical trials

3 unchanged sentences

with patient stipends.

At November 30, 2025, and November 30, 2024, cost of revenue was $ 18,643 and $ 16,165 , respectively.

At February 28, 2026, and February 28, 2025, cost of revenue was $ 3,045 and $ 19,396 respectively.

Note 7 – Stockholders’ Deficiency

12 unchanged sentences

senior to the Common Stock and junior to the Series B Convertible Preferred Stock described below.

At November 30, 2025, and May 31, 2025,

At February 28, 2026, and May 31, 2025,

there were 2,500,000 shares of Series A Stock issued and outstanding.

10 unchanged sentences

be the same, resulting in no change to additional paid-in capital.

At November 30, 2025, and May 31, 2025, there were 2,000 shares

At February 28, 2026, and May 31, 2025, there were 2,000 shares

of Series B Preferred issued and outstanding.

On August 11, 2024, the Board authorized the issuance

of 125,000,000 shares of Common Stock to a related party on May 31, 2025, May 31, 2026, May 31, 2027, and May 31, 2028, as compensation

for his services as treasurer and a director of the Company during the years then ended, if he is serving as treasurer on those dates.

Also, on August 11, 2024, the Board authorized the issuance of, and the Company issued 1,000 shares of Series B Preferred to this related

party as compensation for services to be rendered by him in raising capital.

On August 11, 2024, the Board authorized the

issuance of 125,000,000

shares of Common Stock to a related party on May 31, 2025, May 31, 2026, May 31, 2027, and May 31, 2028, as compensation for his

services as former treasurer and a director of the Company during the years then ended, if he is serving as treasurer on those

Also, on August 11, 2024, the Board authorized the issuance of, and the Company issued 1,000

shares of Series B Preferred to this related party as compensation for services to be rendered by him in raising capital.

On August 11, 2024, the Board authorized the issuance

2 unchanged sentences

as secretary on those dates.

At November 30, 2025, and May 31, 2025, there were

At February 28, 2026, and May 31, 2025, there were

11,626,749,347 shares of Common Stock issued and outstanding.

Note 8 – Share-Based Compensation

On July 20, 2022, the Company adopted its 2022 Equity

Incentive Plan, which provides for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock,

unrestricted stock, restricted stock units and performance awards to directors, officers, employees and consultants, as determined by

the Board, as plan administrator.

The Company will recognize as share-based compensation expense all share-based payments to employees

over the requisite service period (generally the vesting period) in its consolidated statements of operations based on the fair values

of the awards that are issued.

Note 8 – Income Taxes

4 unchanged sentences

assets through future operations.

On December 22, 2017, the 2017 Tax Cuts and Jobs Act

(the “Tax Act”) was enacted into law, making significant changes to the Code.

These changes included a federal corporate tax

rate decrease from 35 % to 21 % for tax years beginning after December 31, 2017, the transition of U.S.

international taxation from a worldwide

tax system to a territorial system and a one-time transition tax on the mandatory deemed repatriation of foreign earnings.

is required to recognize the effect of the tax law changes in the period of enactment, such as re-measuring its U.S.

deferred tax assets

and liabilities, as well as reassessing the net realizability of its deferred tax assets and liabilities.

The Tax Act did not give rise

to any material impact on the balance sheets and statements of operations due to the Company’s historical worldwide loss position

and the full valuation allowance on its net U.S.

deferred tax assets.

Due to changes in ownership provisions of the income

tax laws of the United States of America, net operating loss carryforwards of $ 6,082,513 and $ 5,882,901 at November 30, 2025, and May

tax laws of the United States of America, net operating loss carryforwards of $ 6,174,978 and $ 5,882,901 at February 28, 2026, and May

31, 2025 respectively, for federal income tax reporting purposes are subject to annual limitations.

5 unchanged sentences

Note 9 – Commitments and Contingencies

The Company leases premises of approximately 4,500

square feet located at 6201 Bonhomme Road, Suites 460S and 466S, Houston, Texas.

The lease provided for a base rent of $3,382 per

month, increasing to (i) $3,529 per month on July 1, 2020, (ii) $3,676.04 per month on July 1, 2021, and (iii) $3,823 per

month on July 1, 2022, subject to CPI increase.

On March 23, 2023, the Company amended the lease to extend its term to June 30,

2024, at a base rent of $4,779 per month.

On September 5, 2023, the lease was amended to extend its term to June 30, 2025, at rentals

of $0 per month for the two months ended February 29, 2024, $$4,779 per month for the 10 months ending June 30, 2024, and $4,926 per month

for the 12 months ending June 30, 2025.

This lease was amended on June 18, 2025, to add a one-year term that commenced on June

1, 2025, at a base rent of $1,730 per month.

For information regarding the recording of the right-of-use asset and the lease liability

in the consolidated balance sheets in respect of this lease, see Note 5.

One of the Company’s officers leased 1,400 square

feet at 1625 Main St., Houston, Texas, under a lease the term of which commenced on March 15, 2023, and expired on September 14, 2023,

at a rent of $3,168 per month.

This officer made these premises available to the Company for office space, for which the Company paid

them $2,817 per month.

The lease was renewed for these premises, which commenced on September 15, 2023, and expired on September 14, 2024,

at a rent of $3,164 per month.

The officer made these premises available to the Company for use as office space, for which the Company

paid him $2,817 per month.

On September 3, 2024, one of the Company’s officers

entered into a new lease for these premises.

The Company leases premises known as Suite 435N

located at 6201 Bonhomme Road, Houston, Texas.

This lease was amended on June 18, 2025, to add a one-year term that began on May 1, 2025,

and ends on April 30, 2026.

The amendment provides for a monthly base rent of $1,730.37.

These rates remain subject to the Consumer Price

Index (CPI) clause established in the original lease.

As of the amendment date, the Tenant has a security deposit of $1,632.43.

For information

regarding the recording of the right-of-use asset and the lease liability in the consolidated balance sheets in respect of this lease,

One of the Company’s officers, leases Apartment

202N located at 1625 Main St., Houston, Texas (SoDo on Main North).

The lease term for these premises commenced on September 5, 2025,

and is scheduled to expire on August 4, 2026.

The agreement provides for a Monthly Base Rent of $3,999.00.

In addition to the base rent,

the lease includes various monthly recurring fixed charges, such as a $50.00 Common Area Maintenance Fee, a $15.00 Trash/Recycling Flat

Fee, and a $4.00 Pest Control fee.

The security deposit for this location is $3,333.00.

On September 3, 2024, one of the Company’s

officers entered into a new lease for these premises.

The term of the lease began on September 15, 2024, and expired on August 14, 2025.

has not been renewed and under its terms, it has been renewed on a month-to-month basis.

The officer has made these premises available

to the Company for use as office space, for which the Company has paid him $3,333 per month.

The lease has not been renewed and under its terms, it has been renewed on a month-to-month basis.

The officer has made these premises

available to the Company for use as office space, for which the Company has paid him $3,333 per month.

Note 10 – Related Party Transactions

9 unchanged sentences

In the year ended May 31, 2024, the Company ceased making such payments.

This note bears interest at

the rate of 42.5 % per annum and is to be repaid at the rate of $1,188 per month for 18 months.

The Company believes that,

at November 30, 2025, the outstanding balance of this loan, including interest, was $ 16,465 and that it is in default or has been written

off by the lender.

This note bears interest

at the rate of 42.5 %

per annum and is to be repaid at the rate of $1,188 per month for 18 months.

On July 26, 2024, the Company entered into an

agreement with John Jones, Barbara Kamienski, and Dante Picazo to formalize their business relationship and restructure existing debt.

Under this agreement, the Company recognized the “Jones Note,” which was a promissory note originally dated April 30, 2024,

in the principal amount of $ 291,451 .25 in favor of Mr.

Jones and Ms.

As part of this restructuring, the interest rate on the

Jones Note was reduced to 30% annually (2.5% monthly), and the monthly payment was set at $5,000.00.

Additionally, Mr.

Jones agreed to

return eight prior promissory notes, dated between July 2023 and March 2024, to be marked as paid in full.

In consideration for his services

as a Director and Treasurer, as well as capital-raising obligations, the Company agreed to issue Mr.

Jones 2,000,000 shares of Series

B Preferred Stock and 500,000,000 shares of common stock, with the latter vesting in installments through 2028.

On November 1, 2025, the Company issued a new promissory

17 unchanged sentences

The balance of related party liabilities owed to certain

shareholders totaled $ 793,196 and $ 623,474 at November 30, 2025, and May 31, 2025, respectively.

shareholders totaled $ 845,294 and $ 623,474 on February 28, 2026, and May 31, 2025, respectively.

The balance of related party receivables

owed by certain shareholders totaled $ 0 and $ 9,155 at November 30, 2025, and May 31, 2025.

owed by certain shareholders totaled $ 0 and $ 9,155 at February 28, 2026, and May 31, 2025.

Note 11 – Off-Balance-Sheet Arrangements

1 unchanged sentence

Note 12 – Concentration of Risk

The Company had three customers that provided 99 %

of gross revenue for the quarter ended November 30, 2025, and two customers that provided 98 % of gross revenue for the quarter ended November

had one customer that provided 99 % of gross revenue for the quarter ended February 28, 2026, a nd

three customers that provided 51 %, 30 % and 15 % of gross revenue for the quarter ended February 28, 2025.

Note 13 – Subsequent Events

On December 31, 2025, the Company terminated its Pharmacology

University business.

On March 20, 2026, the Company entered into an

agreement resulting in the issuance of 20,000,000 shares of its common stock to George Opara.

The shares were issued as compensation for

professional services rendered to the Company and were valued at an aggregate price of $5,000, or $0.00025 per share.

Management has evaluated all other subsequent events

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements